Poland · Delayed Price · Currency is PLN Pharmena Statistics
Total Valuation
Pharmena has a market cap or net worth of PLN 34.97 million. The enterprise value is 34.90 million.
| Market Cap | 34.97M |
| Enterprise Value | 34.90M |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmena has 11.14 million shares outstanding.
| Current Share Class | 11.14M |
| Shares Outstanding | 11.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.89% |
| Owned by Institutions (%) | 1.86% |
| Float | 3.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.79 |
| PB Ratio | 3.82 |
| P/TBV Ratio | 4.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.64, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.64 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -166.63 |
Financial Efficiency
Return on equity (ROE) is -26.17% and return on invested capital (ROIC) is -55.64%.
| Return on Equity (ROE) | -26.17% |
| Return on Assets (ROA) | -17.09% |
| Return on Invested Capital (ROIC) | -55.64% |
| Return on Capital Employed (ROCE) | -33.51% |
| Weighted Average Cost of Capital (WACC) | 7.28% |
| Revenue Per Employee | 229,286 |
| Profits Per Employee | -394,429 |
| Employee Count | 7 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.38 |
Taxes
In the past 12 months, Pharmena has paid 10,000 in taxes.
| Income Tax | 10,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.36% in the last 52 weeks. The beta is 0.56, so Pharmena's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -12.36% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 3.38 |
| Relative Strength Index (RSI) | 41.42 |
| Average Volume (20 Days) | 2,637 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmena had revenue of PLN 1.61 million and -2.76 million in losses. Loss per share was -0.25.
| Revenue | 1.61M |
| Gross Profit | 1.36M |
| Operating Income | -3.17M |
| Pretax Income | -2.75M |
| Net Income | -2.76M |
| EBITDA | -3.14M |
| EBIT | -3.17M |
| Loss Per Share | -0.25 |
Balance Sheet
The company has 411,000 in cash and 340,000 in debt, with a net cash position of 71,000 or 0.01 per share.
| Cash & Cash Equivalents | 411,000 |
| Total Debt | 340,000 |
| Net Cash | 71,000 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 9.17M |
| Book Value Per Share | 0.82 |
| Working Capital | 7.31M |
Cash Flow
In the last 12 months, operating cash flow was -3.25 million and capital expenditures -364,000, giving a free cash flow of -3.61 million.
| Operating Cash Flow | -3.25M |
| Capital Expenditures | -364,000 |
| Depreciation & Amortization | 29,000 |
| Net Borrowing | -84,000 |
| Free Cash Flow | -3.61M |
| FCF Per Share | -0.32 |
Margins
Gross margin is 84.86%, with operating and profit margins of -197.26% and -172.02%.
| Gross Margin | 84.86% |
| Operating Margin | -197.26% |
| Pretax Margin | -171.40% |
| Profit Margin | -172.02% |
| EBITDA Margin | -195.45% |
| EBIT Margin | -197.26% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.85, which amounts to a dividend yield of 27.07%.
| Dividend Per Share | 0.85 |
| Dividend Yield | 27.07% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 27.07% |
| Earnings Yield | -7.89% |
| FCF Yield | -10.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmena has an Altman Z-Score of 20.39 and a Piotroski F-Score of 2.
| Altman Z-Score | 20.39 |
| Piotroski F-Score | 2 |